Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems.

Despite the widespread use of L-3,4-dihydroxyphenylalanine (L-DOPA) as the gold standard for dopamine (DA) replacement in Parkinson's Disease (PD), its prolonged administration frequently leads to L-DOPA-induced dyskinesia (LID), a significant therapeutic challenge. Modulating the endocannabinoid system has emerged as a promising approach for managing LID. This study explored whether cannabidiol (CBD), a non-psychoactive compound of Cannabis sativa, and PECS-101, a fluorinated derivative of CBD, could mitigate the onset and progression of LID.

Sex-related differences in cannabidiol's antinociceptive efficacy in a trigeminal neuralgia rodent model.

Trigeminal neuralgia (TN) is a severe orofacial pain condition with sex-specific differences in pain responses. Standard treatments offer limited efficacy and significant side effects. We hypothesized that cannabidiol (CBD) alleviates TN-induced allodynia more effectively than carbamazepine in a sex- and dose-dependent manner through neuroimmune mechanisms, including modulation of glia, Fos protein expression, and oxidative stress in the ventrolateral periaqueductal gray (vlPAG) and spinal trigeminal nucleus caudalis (Sp5c).

A journey through cannabidiol in Parkinson's disease.

Parkinson's disease is a chronic neurodegenerative disorder with no known cure characterized by motor symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Non-motor symptoms like cognitive impairment, mood disturbances, and sleep disorders often accompany the disease. Pharmacological treatments for these symptoms are limited and frequently induce significant adverse reactions, underscoring the necessity for appropriate treatment options.

Cannabidiol and pain.

Chronic pain presents significant personal, psychological, and socioeconomic hurdles, impacting over 30% of adults worldwide and substantially contributing to disability. Unfortunately, current pharmacotherapy often proves inadequate, leaving fewer than 70% of patients with relief. This shortfall has sparked a drive to seek alternative treatments offering superior safety and efficacy profiles.